Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

We sought to investigate the clinical profile(s) associated with the discontinuation of lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable hepatocellular carcinoma (HCC). This retrospective study enrolled 177 patients with HCC treated with LEN. Independent factors as...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Shimose, Shigeo, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Okamura, Shusuke, Nakano, Masahito, Suga, Hideya, Kuromatsu, Ryoko, Yamaguchi, Taizo, Kawaguchi, Takumi, Tanaka, Masatoshi, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7408786/
https://ncbi.nlm.nih.gov/pubmed/32664489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071867
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires